相似文献
1
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Proc Natl Acad Sci U S A. 1989 Mar;86(6):2003-7. doi: 10.1073/pnas.86.6.2003.
2
Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1656-60. doi: 10.1073/pnas.88.5.1656.
3
Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Pancreas. 1993 Jan;8(1):88-97. doi: 10.1097/00006676-199301000-00016.
4
Evaluation of receptors for somatostatin in various tumors using different analogs.
J Clin Endocrinol Metab. 1990 Mar;70(3):661-9. doi: 10.1210/jcem-70-3-661.
5
Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
Proc Natl Acad Sci U S A. 1987 Apr;84(8):2502-6. doi: 10.1073/pnas.84.8.2502.
6
Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion.
Proc Soc Exp Biol Med. 1988 Feb;187(2):241-9. doi: 10.3181/00379727-187-42661.
7
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2315-9. doi: 10.1073/pnas.91.6.2315.
8
Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1.
Endocrinology. 1999 Feb;140(2):765-77. doi: 10.1210/endo.140.2.6492.
9
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896-900. doi: 10.1073/pnas.83.6.1896.
10
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7275-9. doi: 10.1073/pnas.84.20.7275.
引用本文的文献
1
Somatostatin and Somatostatin Receptors in Tumour Biology.
Int J Mol Sci. 2023 Dec 28;25(1):436. doi: 10.3390/ijms25010436.
2
Evolution of Neuroendocrine Tumor Therapy.
Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002.
3
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.
Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388.
4
Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3'-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression.
Oncotarget. 2017 Jun 27;8(39):65339-65358. doi: 10.18632/oncotarget.18689. eCollection 2017 Sep 12.
5
Neuroendocrine factors: The missing link in non‑melanoma skin cancer (Review).
Oncol Rep. 2017 Sep;38(3):1327-1340. doi: 10.3892/or.2017.5817. Epub 2017 Jul 13.
6
Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
Mol Endocrinol. 2016 Apr;30(4):479-90. doi: 10.1210/me.2015-1241. Epub 2016 Mar 11.
7
Review of recent advances in analytical techniques for the determination of neurotransmitters.
Anal Chim Acta. 2009 Oct 19;653(1):1-22. doi: 10.1016/j.aca.2009.08.038. Epub 2009 Sep 1.
8
Regulation of colonic apical potassium (BK) channels by cAMP and somatostatin.
Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G159-67. doi: 10.1152/ajpgi.00132.2009. Epub 2009 Apr 30.
9
Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.
Int J Gastrointest Cancer. 2005;35(3):179-85. doi: 10.1385/IJGC:35:3:179.
10
Somatostatin and somatostatin receptor physiology.
Endocrine. 2003 Apr;20(3):255-64. doi: 10.1385/ENDO:20:3:255.
本文引用的文献
1
Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF.
Proc Natl Acad Sci U S A. 1982 Apr;79(8):2574-8. doi: 10.1073/pnas.79.8.2574.
2
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.
J Biol Chem. 1982 Feb 10;257(3):1523-31.
3
A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins.
Biochem Biophys Res Commun. 1981 Jul 30;101(2):517-23. doi: 10.1016/0006-291x(81)91290-0.
4
Effects of gastrointestinal hormones on pancreatic growth.
Cancer. 1981 Mar 15;47(6 Suppl):1640-5. doi: 10.1002/1097-0142(19810315)47:6+<1640::aid-cncr2820471430>3.0.co;2-s.
5
Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.
J Biol Chem. 1980 Sep 25;255(18):8363-5.
6
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
Proc Natl Acad Sci U S A. 1984 Jan;81(1):248-52. doi: 10.1073/pnas.81.1.248.
7
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.
Life Sci. 1982 Sep 13;31(11):1133-40. doi: 10.1016/0024-3205(82)90087-x.
8
The molecular genetics of cancer.
Science. 1987 Jan 16;235(4786):305-11. doi: 10.1126/science.3541204.
9
Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding.
Proc Natl Acad Sci U S A. 1987 Nov;84(22):7832-6. doi: 10.1073/pnas.84.22.7832.
10
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.
Science. 1986 Jun 27;232(4758):1644-6. doi: 10.1126/science.3012781.
Zotero 插件